The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know

References

1. 1.↵
   1. Louis DN,
   2. Aldape K,
   3. Brat DJ, et al

   . Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol 2017;133:1–3 doi:10.1007/s00401-016-1646-x pmid:27909809

   CrossRefPubMed
2. 2.↵
   1. Louis DN,
   2. Aldape K,
   3. Brat DJ, et al

   . cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 2017;27:851–52 doi:10.1111/bpa.12457 pmid:27997995

   CrossRefPubMed
3. 3.↵
   1. Louis DN,
   2. Wesseling P,
   3. Paulus W, et al

   . cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 2018;135:481–84 doi:10.1007/s00401-018-1808-0 pmid:29372318

   CrossRefPubMed
4. 4.↵
   1. Louis DN,
   2. Giannini C,
   3. Capper D, et al

   . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–42 doi:10.1007/s00401-018-1826-y pmid:29497819

   CrossRefPubMed
5. 5.↵
   1. Brat DJ,
   2. Aldape K,
   3. Colman H, et al

   . cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105

   CrossRefPubMed
6. 6.↵
   1. Ellison DW,
   2. Hawkins C,
   3. Jones DTW, et al

   . cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF V600E mutation. Acta Neuropathol 2019;137:683–87 doi:10.1007/s00401-019-01987-0 pmid:30848347

   CrossRefPubMed
7. 7.↵
   1. Brat DJ,
   2. Aldape K,
   3. Colman H, et al

   . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139:603–08 doi:10.1007/s00401-020-02127-9 pmid:31996992

   CrossRefPubMed
8. 8.↵
   1. Louis DN,
   2. Wesseling P,
   3. Aldape K, et al

   . cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-UTRECHT meeting on future CNS tumor classification and grading. Brain Pathol 2020;30:844–56 doi:10.1111/bpa.12832 pmid:32307792

   CrossRefPubMed
9. 9.↵
   1. Ellison DW,
   2. Aldape KD,
   3. Capper D, et al

   . cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020;30:863–66 doi:10.1111/bpa.12866 pmid:32502305

   CrossRefPubMed
10. 10.↵
    1. Louis DN,
    2. Ellison DW,
    3. Brat DJ, et al

    . cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. Brain Pathol 2019;29:469–72 doi:10.1111/bpa.12732 pmid:31038238

    CrossRefPubMed
11. 11.↵
    WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed: Lyon: International Agency for Research on Cancer; 2021
12. 12.↵
    1. Batchala PP,
    2. Muttikkal TJ,
    3. Donahue JH, et al

    . Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 2019;40:426–42 doi:10.3174/ajnr.A5957 pmid:30705071

    Abstract/FREE Full Text
13. 13.↵
    1. Patel SH,
    2. Poisson LM,
    3. Brat DJ, et al

    . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

    Abstract/FREE Full Text
14. 14.↵
    1. Doig D,
    2. Kachramanoglou C,
    3. Dumba

    M, et al. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade. Clin Radiol 2021;76:785 doi:10.1016/j.crad.2021.06.015 pmid:34289936

    CrossRefPubMed
15. 15.↵
    1. Chen Y,
    2. Tian T,
    3. Guo X, et al

    . Polymorphous low-grade neuroepithelial tumor of the young: case report and review focus on the radiological features and genetic alterations. BMC Neurol 2020;20:123 doi:10.1186/s12883-020-01679-3 pmid:32252664

    CrossRefPubMed
16. 16.↵
    1. Benson JC,
    2. Summerfield D,
    3. Carr C, et al

    . Polymorphous low-grade neuroepithelial tumor of the young as a partially calcified intra-axial mass in an adult. AJNR Am J Neuroradiol 2020;41:573–78 doi:10.3174/ajnr.A6500 pmid:32217553

    Abstract/FREE Full Text
17. 17.↵
    1. Ryall S,
    2. Zapotocky M,
    3. Fukuoka K, et al

    . Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37:569–83 doi:10.1016/j.ccell.2020.03.011 pmid:32289278

    CrossRefPubMed
18. 18.↵
    1. Ross JL,
    2. Velazquez Vega J,
    3. Plant A, et al

    . Tumor immune landscape of paediatric high-grade gliomas. Brain 2021;144:2594–2609 doi:10.1093/brain/awab155 pmid:33856022

    CrossRefPubMed
19. 19.↵
    1. Roux A,
    2. Pallud J,
    3. Saffroy R, et al

    . High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro Oncol 2020;22:1190–1202 doi:10.1093/neuonc/noaa024 pmid:32025728

    CrossRefPubMed
20. 20.↵
    1. Yekula A,
    2. Gupta M,
    3. Coley N, et al

    . Adult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: case report and review of the literature. Int J Surg Case Rep 2020;68:124–28 doi:10.1016/j.ijscr.2020.02.046 pmid:32145563

    CrossRefPubMed
21. 21.↵
    1. Aboian MS,
    2. Solomon DA,
    3. Felton E, et al

    . Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795–800 doi:10.3174/ajnr.A5076 pmid:28183840

    Abstract/FREE Full Text
22. 22.↵
    1. Muñoz Pérez JP,
    2. Muchart J,
    3. Santa-María López V, et al

    . Targeted therapy for pediatric low-grade glioma. Childs Nerv Syst 2021;37:2511–20 doi:10.1007/s00381-021-05138-3 pmid:33864514

    CrossRefPubMed
23. 23.↵
    1. Bender K,
    2. Perez E,
    3. Chirica M, et al

    . High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity. J Neurooncol 2021;153:109–20 doi:10.1007/s11060-021-03749-z pmid:33905054

    CrossRefPubMed
24. 24.↵
    1. Chen W,
    2. Soon YY,
    3. Pratiseyo PD, et al

    . Central nervous system neuroepithelial tumors with MN1-alteration: an individual patient data meta-analysis of 73 cases. Brain Tumor Pathol 2020;37:145–53 doi:10.1007/s10014-020-00372-0 pmid:32601775

    CrossRefPubMed
25. 25.↵
    1. Hirose T,
    2. Nobusawa S,
    3. Sugiyama K, et al

    . Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement. Brain Pathol 2018;28:684–94 doi:10.1111/bpa.12565 pmid:28990708

    CrossRefPubMed
26. 26.↵
    1. Mhatre R,
    2. Sugur HS,
    3. Nandeesh BN

    , et al. MN1 rearrangement in astroblastoma: study of eight cases and review of literature. Brain Tumor Pathol 2019;36:112–20 doi:10.1007/s10014-019-00346-x pmid:31111274

    CrossRefPubMed
27. 27.↵
    1. Deng MY,
    2. Sill M,
    3. Sturm D, et al

    . Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC): a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathol Appl Neurobiol 2020;46:422–30 doi:10.1111/nan.12590 pmid:31867747

    CrossRefPubMed
28. 28.↵
    1. Lucas CH,
    2. Villanueva-Meyer JE,
    3. Whipple N, et al

    . Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol 2020;30:479–94 doi:10.1111/bpa.12797 pmid:31609499

    CrossRefPubMed
29. 29.↵
    1. Chiang JC,
    2. Harreld JH,
    3. Tanaka R, et al

    . Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysis. Neuro Oncol 2019;21:800–08 doi:10.1093/neuonc/noz037 pmid:30726976

    CrossRefPubMed
30. 30.↵
    1. Lecler A,
    2. Broquet V,
    3. Bailleux J, et al

    . Advanced multiparametric magnetic resonance imaging of multinodular and vacuolating neuronal tumor. Eur J Neurol 2020;27:1561–69 doi:10.1111/ene.14264 pmid:32301260

    CrossRefPubMed
31. 31.↵
    1. Nunes RH,
    2. Hsu CC,
    3. da Rocha AJ, et al

    . Multinodular and vacuolating neuronal tumor of the cerebrum: a new “leave me alone” lesion with a characteristic imaging pattern. AJNR Am J Neuroradiol 2017;38:1899–1904 doi:10.3174/ajnr.A5281 pmid:28705817

    Abstract/FREE Full Text
32. 32.↵
    1. Lecler A,
    2. Bailleux J,
    3. Carsin B, et al

    ; ENIGMA Investigation Group (EuropeaN Interdisciplinary Group for MVNT Analysis). Multinodular and vacuolating posterior fossa lesions of unknown significance. AJNR Am J Neuroradiol 2019;40:1689–94 doi:10.3174/ajnr.A6223 pmid:31558497

    Abstract/FREE Full Text
33. 33.↵
    1. Kupp R,
    2. Ruff L,
    3. Terranova S, et al

    . ZFTA-translocations constitute ependymoma chromatin remodeling and transcription factors. Cancer Discov 2021;11:2216–29 doi:10.1158/2159-8290.CD-20-1052 pmid:33741711

    Abstract/FREE Full Text
34. 34.↵
    1. Wang G,
    2. Jia Y,
    3. Ye Y, et al

    . Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis. J Transl Med 2021;19:174 doi:10.1186/s12967-021-02834-1 pmid:33902636

    CrossRefPubMed
35. 35.↵
    1. Witt H,
    2. Mack SC,
    3. Ryzhova M, et al

    . Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011;20:143–57 doi:10.1016/j.ccr.2011.07.007 pmid:21840481

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Raffeld M,
    2. Abdullaev Z,
    3. Pack SD, et al

    . High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun 2020;8:101 doi:10.1186/s40478-020-00973-y pmid:32641156

    CrossRefPubMed
37. 37.↵
    1. Reis J,
    2. Stahl R,
    3. Zimmermann H, et al

    . Advanced MRI findings in medulloblastomas: relationship to genetic subtypes, histopathology, and immunohistochemistry. J Neuroimaging 2021;31:306–16 doi:10.1111/jon.12831 pmid:33465267

    CrossRefPubMed
38. 38.↵
    1. Coltin H,
    2. Sundaresan L,
    3. Smith KS, et al

    . Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathol 2021;142:859–71 doi:10.1007/s00401-021-02358-4 pmid:34409497

    CrossRefPubMed
39. 39.↵
    1. Skowron P,
    2. Farooq H,
    3. Cavalli FM, et al

    . The transcriptional landscape of SHH medulloblastoma. Nat Comm 2021;12:1749 doi:10.1038/s41467-021-21883-0 pmid:33741928

    CrossRefPubMed
40. 40.↵
    1. Cai C

    . SWI/SNF deficient central nervous system neoplasms. Semin Diagn Pathol 2021;38:167–74 doi:10.1053/j.semdp.2021.03.003 pmid:33762087

    CrossRefPubMed
41. 41.↵
    1. Tauziede-Espariat A,
    2. Pierron G,
    3. Seigfried A, et al

    . The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of “CNS tumors with BCOR internal tandem duplication.” Acta Neuropathol Commun 2020;8:178 doi:10.1186/s40478-020-01064-8 pmid:33138864

    CrossRefPubMed
42. 42.↵
    1. Shih RY,
    2. Koeller KK

    . Embryonal tumors of the central nervous system: from the radiologic pathology archives. Radiographics 2018;38:525–41 doi:10.1148/rg.2018170182 pmid:29528832

    CrossRefPubMed
43. 43.↵
    1. Korshunov A,
    2. Okonechnikov K,
    3. Schmitt-Hoffner F, et al

    . Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. Acta Neuropathol Commun 2021;9:20 doi:10.1186/s40478-021-01118-5 pmid:33536079

    CrossRefPubMed
44. 44.↵
    1. Thomas C,
    2. Wefers A,
    3. Bens S, et al

    . Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathol 2020:277–86 doi:10.1007/s00401-019-02094-w pmid:31732806

    CrossRefPubMed
45. 45.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P

    , et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

    CrossRefPubMed
46. 46.↵
    1. Lopes MB

    . The 2017 World Health Organization Classification of Tumors of the Pituitary Gland: a summary. Acta Neuropathol 2017;134:521–55 doi:10.1007/s00401-017-1769-8 pmid:28821944

    CrossRefPubMed